A study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals’ RSV investigational vaccine based on viral proteins encoded by chimpanzee-derived adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive infants

Trial Identifier: 204838
Sponsor: GlaxoSmithKline
Start Date: January 2017
Primary Completion Date: February 2019
Study Completion Date: November 2020
Condition: Respiratory Syncytial Virus Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

No locations posted.